EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Direct delivery of immune modulators to tumour‐infiltrating lymphocytes using engineered extracellular vesicles

Xiabing Lyu, Tomoyoshi Yamano, Kanto Nagamori, Shota Imai, Toan Van Le, Dilireba Bolidong, Makie Ueda, Shota Warashina, Hidefumi Mukai, Seigo Hayashi, Kazutaka Matoba, Taito Nishino und 1 weitere

Journal of Extracellular Vesicles · 2025

DOI: 10.1002/jev2.70035 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Extracellular Vesicles, 2025. Verfasst von Xiabing Lyu und 12 weiteren Autor:innen. Beteiligte Einrichtung: WPI Nano Life Science Institute (NanoLSI), Kanazawa University, Kanazawa, Japan. Hauptthemen laut MEDLINE: Extracellular Vesicles, Lymphocytes, Tumor-Infiltrating, Immunologic Factors. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Agency for Medical Research and Development, Japan Science and Technology Corporation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Extracellular vesicles (EVs) are important mediators of cell–cell communication, including immune regulation. Despite the recent development of several EV‐based cancer immunotherapies, their clinical efficacy remains limited. Here, we created antigen‐presenting EVs to express peptide‐major histocompatibility complex (pMHC) class I, costimulatory molecule and IL‐2. This enabled the selective delivery of multiple immune modulators to antigen‐specific CD8 + T cells, promoting their expansion in vivo without severe adverse effects. Notably, antigen‐presenting EVs accumulated in the tumour microenvironment, increasing IFN‐γ + CD8 + T cell and decreasing exhausted CD8 + T cell numbers, suggesting that antigen‐presenting EVs transformed the ‘cold’ tumour microenvironment into a ‘hot’ one. Combination therapy with antigen‐presenting EVs and anti‐PD‐1 demonstrated enhanced anticancer immunity against established tumours. We successfully engineered humanized antigen‐presenting EVs, which selectively stimulated tumour antigen‐specific CD8 + T cells. In conclusion, engineering EVs to co‐express multiple immunomodulators represents a promising method for cancer immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Extracellular VesiclesLymphocytes, Tumor-InfiltratingImmunologic FactorsAnimalsMiceHumansCD8-Positive T-LymphocytesTumor MicroenvironmentImmunotherapyCell Line, TumorNeoplasmsMice, Inbred C57BL

Stichwörter der Autor:innen

antigen presentationcancer immunotherapydrug deliveryextracellular vesicletargeted cytokine delivery

Substanzen

Immunologic Factors

Autor:innen und Institutionen

  • WPI Nano Life Science Institute (NanoLSI), Kanazawa University, Kanazawa, Japan.
  • Department of Immunology, Graduate School of Medicine, Kanazawa University, Kanazawa, Japan.
  • Laboratory for Molecular Delivery and Imaging Technology, RIKEN Center for Biosystems Dynamics Research, Kobe, Japan.
  • Department of Pharmaceutical Informatics, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan.
  • Biological Research Laboratories, Nissan Chemical Corporation, Saitama, Japan.

ORCID-Profile: Rikinari Hanayama

Förderung

  • Japan Agency for Medical Research and Development
  • Japan Science and Technology Corporation

Zitieren

APA

Lyu, X., Yamano, T., Nagamori, K., Imai, S., Van Le, T., Bolidong, D., Ueda, M., Warashina, S., Mukai, H., Hayashi, S., Matoba, K., Nishino, T., & Hanayama, R. (2025). Direct delivery of immune modulators to tumour‐infiltrating lymphocytes using engineered extracellular vesicles. Journal of Extracellular Vesicles. https://doi.org/10.1002/jev2.70035

Vancouver

Lyu X, Yamano T, Nagamori K, Imai S, Van Le T, Bolidong D, et al. Direct delivery of immune modulators to tumour‐infiltrating lymphocytes using engineered extracellular vesicles. Journal of Extracellular Vesicles. 2025. doi:10.1002/jev2.70035

BibTeX
@article{Lyu2025,
  author = {Lyu, Xiabing and Yamano, Tomoyoshi and Nagamori, Kanto and Imai, Shota and Van Le, Toan and Bolidong, Dilireba and Ueda, Makie and Warashina, Shota and Mukai, Hidefumi and Hayashi, Seigo and Matoba, Kazutaka and Nishino, Taito and Hanayama, Rikinari},
  title = {Direct delivery of immune modulators to tumour‐infiltrating lymphocytes using engineered extracellular vesicles},
  journal = {Journal of Extracellular Vesicles},
  year = {2025},
  doi = {10.1002/jev2.70035}
}
Kostenlos starten →